RPT1G
Oncology (unspecified solid tumors)
Phase 1Active
Key Facts
Indication
Oncology (unspecified solid tumors)
Phase
Phase 1
Status
Active
Company
About Remedy Plan Therapeutics
Remedy Plan Therapeutics is pioneering a novel approach to NAMPT inhibition, a core metabolic enzyme implicated in over 20 diseases including cancer, autoimmune disorders, and obesity. Its proprietary drug screening platform has yielded RPT1G, a first-in-class clinical candidate with an unprecedented allosteric mechanism aimed at delivering efficacy without the severe toxicity of prior NAMPT inhibitors. The company is advancing RPT1G in oncology while leveraging its platform to discover new drugs for autoimmune and metabolic indications. With its lead program now in Phase 1, Remedy Plan is positioned to validate a new therapeutic paradigm for a high-value but historically intractable target.
View full company profileTherapeutic Areas
Other Oncology (unspecified solid tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| Surv.m-CRA-1 | Surv Biopharma | Phase 1 |